Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | May 18, 2024
Discovery & Translation

Brain-penetrant AAV capsid progress at ASGCT 

Companies and academics showcase two approaches to make AAV capsids with enhanced brain targeting and suppressed liver targeting
BioCentury | May 15, 2024
Discovery & Translation

Voyager’s journey to identify a new shuttle for bringing gene therapies into the brain

Biotech identifies ALPL as a cross-species cell surface receptor mediating BBB crossing of AAV capsid family
BioCentury | Apr 28, 2023
Discovery & Translation

MMP3 gene therapy for glaucoma; plus programmable mRNA translation and more

BioCentury’s roundup of translational news
BioCentury | Jun 1, 2009
Clinical News

Zeltia preclinical data

BioCentury | Jan 7, 2008
Finance

New products to watch

BioCentury | Jul 16, 2007
Company News

Drug Royalty, University of Michigan deal

BioCentury | Jul 11, 2007
Company News

Drug Royalty acquires FluMist royalties

BioCentury | May 21, 2007
Clinical News

CAIV-T vaccine regulatory update

BioCentury | May 21, 2007
Finance

Ebb & Flow

Items per page:
1 - 10 of 78
Help Center
Username
Request a Demo
Request Training
Ask a Question